Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Adlai Nortye Ltd. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
09.07. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
ADLAI NORTYE Aktie jetzt für 0€ handeln | |||||
02.06. | H.C. Wainwright stuft Adlai Nortye nach Studienergebnissen herab | 1 | Investing.com Deutsch | ||
02.06. | H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS | 1 | Investing.com | ||
30.05. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
30.04. | Adlai Nortye Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 38,460 | +0,40 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,090 | -0,17 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
MINERALYS THERAPEUTICS | 37,290 | -0,35 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
HILLEVAX | 2,090 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. | EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping... ► Artikel lesen | |
CG ONCOLOGY | 37,510 | +4,89 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
BIONTECH | 82,95 | -0,90 % | Evotec Aktie: Endlich Hoffnung? - BioNTech, Deutsche Bank, Deutsche Telekom, Deutz und RWE im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SCISPARC | 4,365 | +137,23 % | Morning Market Movers: SciSparc, HIND, SQFT, FGNX See Big Swings | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
EVOTEC | 6,214 | +1,04 % | Evotec-Aktie mit Kursverlusten (6,092 €) | Im deutschen Wertpapierhandel liegt die Evotec-Aktie gegenwärtig im Minus. Der jüngste Kurs betrug 6,09 Euro. Ein Preisabschlag in Höhe von 0,058 Euro müssen derzeit die Aktionäre von Evotec hinnehmen.... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 44,030 | +4,83 % | Praxis Precision Medicines: Piper Sandler bestätigt "Overweight" nach positiven Studiendaten | ||
VALNEVA | 4,168 | +9,97 % | Valneva-Aktie springt an: Chikungunya-Alarm in Italien! | Die Ausbreitung des Chikungunya-Virus, welches durch die Tigermücke übertragen wird, bereitet zusehends auch in Europa Probleme. Allen voran in Italien wachsen die Sorgenfalten. Die Aktie des europäischen... ► Artikel lesen | |
JANUX THERAPEUTICS | 23,460 | +0,21 % | Janux is a new Buy at Truist ahead of catalyst rich H2 | ||
BEAM THERAPEUTICS | 22,470 | -1,92 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
PHATHOM PHARMACEUTICALS | 11,000 | +0,18 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 35,430 | -0,95 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 40,060 | -3,33 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential |